APOC3 and lung carcinoma: Table 3 shows the proportions mediated by neutral ceramidase regarding the negative effect of APOB inhibition on lung cancer risk in smokers via ApoB and TG reduction (8.1% and 9.5%, respectively) and the negative effect of APOC3 inhibition on LUAD risk via ApoB reduction (8.7%). Figure 6 illustrates schematic diagrams of the direct and indirect effects of LLDs on lung cancer and the mediation by neutral ceramidase.